Compare OXSQ & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXSQ | NVCT |
|---|---|---|
| Founded | 2003 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.4M | 167.0M |
| IPO Year | N/A | 2022 |
| Metric | OXSQ | NVCT |
|---|---|---|
| Price | $1.84 | $6.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.33 |
| AVG Volume (30 Days) | ★ 728.9K | 89.1K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | ★ 22.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,142,565.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.56 | $4.44 |
| 52 Week High | $2.87 | $11.52 |
| Indicator | OXSQ | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 46.79 | 54.35 |
| Support Level | $1.84 | $5.85 |
| Resistance Level | $1.91 | $6.21 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 18.00 | 70.91 |
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.